Cell Genesys halts GVAX program, cuts jobs

Published on Thursday 16 October 2008 - 15:29

Summary :
Cell Genesys has terminated a late-stage trial of GVAX immunotherapy in patients with prostate cancer. The company had 626 patients enrolled in the trial. The decision to halt the trial was made...
Read more

Information source

http://www.fiercebiotech.com/news/frontpage

Website description
Get the latest news on the biotech industry, biotech companies, FDA approval and clinical research. Sign up today for the biotech industry

Articles published on this website : 1 / 7 days - 4 / 30 days

FDA approves prostate cancer drug Degarelix Amgen files for crucial denosumab approval Synta gets $15M milestone from GSK AZ returns rights to two oncology programs OncoGenex shares soar on promising prostate cancer data

Other articles published on other websites on the same day

Nicotine May Spur Breast Cancer's Spread http://empowher.com/ Louis Church Named CEO at Echt Cancer Treatment Group http://www.redorbit.com/ Health Winners & Losers: Gilead http://www.thestreet.com/ Cell Genesys Halts Another Late-Stage GVAX Trial http://www.fdanews.com/ Predictive Biosciences Closes $21.75 Million Round to Help Detect Cancer From Urine http://www.xconomy.com/ Circulating Tumor Cells Predict Survival http://www.renalandurologynews.com/ Miraculins Announces Enrollment of First Patient in Second Pivotal Prostate Cancer Study http://www.marketwire.com/ Truth In Numbers: How Statistics Can Mislead http://www.pharmalot.com/ Optimized Radiation for Prostate Cancer Therapy http://idw-online.de/ Wanna Veg? http://www.collegeotr.com/